Motif Bio plc Refining commercialisation strategy through new board addition

Motif Bio plc

Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the appointment of Dr. Craig T. Albanese to the Company’s Board as Non-Executive Director with immediate effect.

Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women’s health, primarily in the Stanford Children’s Hospital, New-York Presbyterian Hospital, Morgan Stanley Children’s Hospital and the Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Paediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost-effective way.

Richard Morgan, Chairman of Motif Bio plc, commented: “I am delighted to welcome Craig to the Board of Motif Bio. We have seen great progress in the development of iclaprim, our lead antibiotic for serious Gram-positive infections, and with the publication of the successful completion of the first Phase III clinical trial, the Board is now increasingly focused on the commercialisation of iclaprim in the US. Craig’s experience and knowledge of both the clinical reality and operational activities of large hospital groups will prove invaluable in refining our commercialisation strategy for iclaprim. We look forward to his input to the team.”

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index